If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Product Launch » Resource Allocation
Download FREE Excerpt
8 Info Graphics
26 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
There has been a flurry of new oncology products approved since 2010, but not all of them have had successful launches. Given the complexity of the oncology market, it is sometimes difficult to know where and how much to invest before, during and after a product's launch.
This benchmarking study is designed to provide investment and staffing benchmarks for oncology products that were launched in 2013 and later (and have no second indication as of 2017). The study focuses on two types of products: those that have launched recently and those that are single (sole) indication brands. The research includes total investment benchmarks across pre-launch, launch and post-launch periods as well as investment benchmarks across 10 key activities before and during launch. There are also staffing benchmarks for both types of products. The study will help marketing and brand leaders identify investment priorities for new oncology products across pre-launch, launch and post-launch activities.
This analysis probes Oncology product staffing levels for 12 companies and 20 U.S. project launches. Executives at the VP level, Functional Heads, Senior Directors and Directors were among the participants who informed this study. The analysis examines staffing allocations at various launch stages as well as across critical Medical and Commercial activities for various market-entry situations.
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Manufacturing; Consumer Products; Diagnostic; Medical Device
EMD Serono; Tesaro; Amgen; Pfizer; OTSUKA; Nektar Therapeutics; Medivation; Astellas; Novartis; Bayer; Lilly; Regeneron